Findings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
A study examining a broader range of domains among patients receiving cystectomy found a large signal of differences in health-related quality of life.
Recurrence is commonly associated with low-grade upper tract urothelial carcinoma and may be predicted by smoking status and tumor size.
Adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel may be the new standard of care for the treatment of patients with de novo metastatic castration-sensitive prostate cancer.
Published: December 2nd 2021 | Updated:
